Risk prediction in heart failure using invasive hemodynamics

利用有创血流动力学预测心力衰竭风险

阅读:1

Abstract

AIMS: Risk stratification in patients with heart failure patients is crucial. The prognostic value of invasive hemodynamic parameters measured by right heart catheterization compared to established risk scores remains unknown. METHODS AND RESULTS: This retrospective analysis included 883 patients. The combined endpoint was all-cause mortality, heart transplantation or left ventricular assist device implantation. A Cox proportional hazards model assessed the impact of invasive parameters, cardiac biomarkers, and patient characteristics, comparing them with the Seattle Heart Failure Model (SHFM) and the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Score. A new score was created including mean pulmonary arterial (PA) pressure, mean right atrial pressure, mean pulmonary artery wedge pressure (PAWP), age, N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), mixed venous oxygen saturation (SVO2), creatinine, and presence of ischemic cardiomyopathy. Mean, diastolic, and systolic PA pressure, mean right atrial pressure, mean PAWP, SVO2 and cardiac index were significant predictors for the primary endpoint reached by 467/883 (53%) patients, in a multiple Cox proportional hazards model (p < 0.001). The predictive value was diminished in a subgroup of patients with ischemic cardiomyopathy. We used invasive parameters, age, NT-proBNP, hsTnT(,) creatinine presence of ischemic cardiomyopathy and sex to develop a new model for risk stratification. This new score showed better performance compared to the SHFM and MAGGIC score in predicting the primary endpoint at 6, 12 and 24 months (area under the curve 0.76, 0.78 and 0.77 vs 0.71/0.69, 0.70/0.68 and 0.70/0.70). CONCLUSION: Invasive hemodynamics provides valuable measurements for predicting outcome in heart failure with reduced ejection fraction and show better performance than established risk models when combined with cardiac biomarkers and other clinical variables in this particular cohort.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。